We are live on ! Find out more
VCYT icon

Veracyte

111 hedge funds and large institutions have $340M invested in Veracyte in 2018 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 45 increasing their positions, 16 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,800% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 2

181% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 16

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

48% more funds holding

Funds holding: 75111 (+36)

47% more capital invested

Capital invested by funds: $231M → $340M (+$108M)

18.04% more ownership

Funds ownership: 72.14%90.18% (+18%)

Holders
111
Holders Change
+36
Holders Change %
+48%
% of All Funds
2.54%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
38
Increased
45
Reduced
16
Closed
2
Calls
$780K
Puts
Net Calls
+$780K
Net Calls Change
+$18K

VCYT Hedge Fund Activity: Q3 2018 in Review

111 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q3 2018, worth a combined $340M — up 47% from $231M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new VCYT positions and 2 closed out — a net gain of 36 holders — while 45 added to existing stakes and 16 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $39.9M. The largest seller was Acuta Capital Partners, cutting an estimated $17.3M.

  • 111 institutional investors held Veracyte (VCYT) as of Q3 2018, up from 75 in Q2 2018.
  • Funds reported $340M of Veracyte stock for Q3 2018, up 47% quarter-over-quarter.
  • 38 funds opened new Veracyte positions in Q3 2018 and 2 closed out, a net change of +36 holders.
  • The largest Veracyte buyer in Q3 2018 was Versant Venture Management, an estimated $39.9M added.
  • The largest Veracyte seller in Q3 2018 was Acuta Capital Partners, an estimated $17.3M sold.

Based on aggregated 13F filings for Q3 2018.